Comparing Cronos Group (NASDAQ:CRON) and Eton Pharmaceuticals (NASDAQ:ETON)

Eton Pharmaceuticals (NASDAQ:ETON) and Cronos Group (NASDAQ:CRON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Risk & Volatility

Eton Pharmaceuticals has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Institutional and Insider Ownership

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Eton Pharmaceuticals and Cronos Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Cronos Group	39.08%	4.85%	4.62%

Valuation & Earnings

This table compares Eton Pharmaceuticals and Cronos Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95 million	19.75	-$4.60 million	$0.38	145.39
Cronos Group	$146.59 million	8.07	-$9.45 million	$0.20	16.05

Eton Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Eton Pharmaceuticals and Cronos Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	0	2	4	0	2.67
Cronos Group	0	2	3	0	2.60

Eton Pharmaceuticals presently has a consensus price target of $67.50, suggesting a potential upside of 22.17%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 28.35%. Given Eton Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Cronos Group.

Summary

Eton Pharmaceuticals beats Cronos Group on 11 of the 13 factors compared between the two stocks.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

About Cronos Group

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.